Rocket Lab Delivers MDA Satellites, But Neutron and Iridium Remain Key

What happened

Rocket Lab successfully deployed eight satellites for MDA Space under a $143 million contract, marking a key milestone and reducing the risk of delivery delays that were previously flagged in the master report. While this is a positive execution data point for the Space Systems segment, it does not address the two primary catalysts that will determine the stock's next move: completion of Neutron first-stage qualification with a firm launch window, and the financing structure for the pending Iridium acquisition. The master report's WAIT rating is based on the view that at $80 per share, the stock already prices in timely Neutron progress and manageable Iridium financing, leaving no margin of safety. The successful MDA deployment confirms operational competence but does not change the binary nature of upcoming proof points. Therefore, the investment thesis remains unchanged, with the next 6-9 months hinging on Neutron and Iridium developments rather than routine contract execution.

Implication

The MDA satellite deployment is a welcome operational achievement that lowers one execution risk, but it is unlikely to re-rate the stock because the market is already focused on Neutron timing and Iridium financing. The master report assigns a base case value of $82, a bear case of $64, and a bull case of $96, implying that at $80 the risk/reward is balanced rather than favorable. Investors should monitor the 90-day checkpoints: by November 10, 2026, Rocket Lab must show progress on first-stage qualification and a firm Neutron launch window, and on Iridium approvals and permanent financing. If those milestones slip, the stock could fall toward the bear case; if they are achieved, upside toward the bull case is possible. Until then, the stock is a WAIT, with an attractive entry point near $65.

Thesis delta

The successful MDA satellite deployment is a positive operational data point that reduces the risk of contract-related delivery issues, but it does not alter the core investment thesis. The thesis remains centered on the binary outcomes of Neutron qualification and Iridium financing, which are unresolved. Consequently, the WAIT rating and valuation targets are unchanged.